Morison Enters the Cardiovascular Space by 'Touching More Hearts'

Morison, a pioneer in the Sri Lankan pharmaceutical manufacturing industry with over 60 years of expertise, announced their entry into the cardiovascular space with the launch of three advanced promising therapies: Cilnidipine Tablets IP 5mg and 10mg, Rivaroxaban Tablets 10mg and 20mg, and Bisoprolol Tablets BP 2.5mg and 5mg, all in 30s blister packs. Cilnidipine and Rivaroxaban will be manufactured in Sri Lanka for the first time in Morison's new state-of-the-art pharma manufacturing facility at Homagama.

The new cardiovascular portfolio includes CilniMor (Cilnidipine), a 4th Generation Calcium Channel Blocker for hypertension; BisoMor (Bisoprolol), a cardio-selective beta blocker; and RivoMor (Rivaroxaban), a direct factor Xa inhibitor anticoagulant. All medications are quality assured in compliance with pharmacopeial test parameters.

Morison marked this historic milestone with a distinctive launch event attended by leading healthcare professionals and institutional officials on 26^th of February 2025, at Cinnamon Grand, with the theme of “Touching More Hearts”. The highlight of the evening was a panel discussion featuring eminent consultants representing Cardiologists, Endocrinologists and Physicians, who discussed the new therapies and their impact on Sri Lanka's growing NCD challenges.

Dinesh Athapaththu, Managing Director, Morison Ltd said, “At Morison, we choose to take the high road. For us, it’s not just about churning out tablets. We are conscious of the fact that behind every tablet we produce is a person trusting us at their most vulnerable times. Therefore, for us it is not merely a business, but more of a responsibility we take to heart.”

Staying true to their purpose of 'Making Premium Healthcare Affordable', Morison is committed to providing essential medications at significantly lower prices compared to current market rates. CilniMor will be available at LKR 30.00 (5mg) and LKR 45.00 (10mg) per tablet, RivoMor will be available at LKR 60.00 (10mg) and LKR 90.00 (20mg) per tablet, while BisoMor is priced at LKR 15.00 (2.5mg) and LKR 20.00 (5mg) per tablet.  The pricing strategy has the potential to save patients up to LKR 30,000+ annually, making these critical medications more accessible to Sri Lankan patients.

The launch of these therapies follows Morison's successful introduction of EmpaMor (Empagliflozin 10mg and 25mg tablets), a diabetes medication that became the market leader within two years of launch.

Morison will continue to drive this transformative journey of building an exclusive homegrown pharmaceutical brand that is uniquely unparallel, contributing to a more self-sufficient pharmaceutical market. With deep Sri Lankan roots and the backing of Hemas Holdings PLC, the company understands the nation's healthcare needs and is committed to delivering latest advanced therapies, combining quality and affordability, while committing to ensure integrity across their value chain. 

01 Image:  Husein Esufally, Chairman of Hemas Holdings PLC, addressing the gathering at the launch of three advanced and promising therapies by Morison

02 Image: Dinesh Athapaththu, Managing Director of Morison, explaining Morison's purpose and efforts behind the launch of advanced therapies

03 Image: A panel discussion among esteemed medical specialists